Story perspectives

Amgen-AstraZeneca Combo Extends Survival by Eight Months in Spain

By Drooid · Oct 24, 2026, 10:13 PM UTC · How we work

Summary

Story summary

Amgen and AstraZeneca combined Imdelltra with Imfinzi in Spain, extending patient survival by eight months.
The trial reduced death risk by 58% for patients with metastatic tumors.
Half of participants experienced cytokine release syndrome, mostly mild, and 1% developed a neurological issue.
Imfinzi plus Pfizer’s Padcev halted bladder cancer progression in 64% of patients versus 45% at two years.

1 of 1

Story summary

Amgen and AstraZeneca combined Imdelltra with Imfinzi in Spain, extending patient survival by eight months.
The trial reduced death risk by 58% for patients with metastatic tumors.
Half of participants experienced cytokine release syndrome, mostly mild, and 1% developed a neurological issue.
Imfinzi plus Pfizer’s Padcev halted bladder cancer progression in 64% of patients versus 45% at two years.